Immunotherapeutics platform Epitopea nabs $13.6m seed deal

Epitopea, a Cambridge, UK and Montreal-based cancer immunotherapeutics company, has secured $13.6 million in seed financing.

25 April 2022•3 mins read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles